A mAb for the detection of the antiretroviral drug emtricitabine. (1st November 2022)

• Record Type: Journal Article
• Authors: Youngpairoj, Ae S.; Vanderford, Thomas H.; Reed, Matthew S.; Granade, Timothy C.; Pau, Chou-Pong; Pohl, Jan; Switzer, William M.; Heneine, Walid
• Is Part Of: AIDS. Volume 36:Number 13(2022)
• Page Start: 1890
• Page End: 1893
• Publication Date: 2022-11-01
• Subjects: AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodicals; Periodicals; 616.9792005
• DOI: 10.1097/QAD.0000000000003357
• Languages: English
• ISSNs: 0269-9370

Abstract

Abstract : Antibody-based testing for emtricitabine (FTC), a critical component of pre-exposure prophylaxis and antiretroviral therapy, would provide low-cost detection for clinical monitoring to improve adherence. We developed a mAb (5D2) to FTC and demonstrated its high specificity and physiologically relevant linear range of detection in a competitive enzyme immunoassay. Thus, this mAb is a key reagent that will enable simple and low-cost lateral flow assays and enzyme immunoassays for adherence monitoring.